Liphorus Pharmaceuticals, a leading brand in the field of cardiovascular disease treatment, is revolutionizing the way we address this widespread health issue. With a focus on the proprotein convertase subtilisin-kexin 9 (PCSK9), Liphorus Pharmaceuticals is dedicated to developing innovative small molecule inhibitors to target PCSK9 and combat hypercholesterolemia. One of the key advantages of Liphorus Pharmaceuticals' approach is the understanding and manipulation of the autocatalytic cleavage process of PCSK9.

By inhibiting this cleavage, Liphorus Pharmaceuticals ensures the production of proteolytically inactive proteins, effectively reducing the risks associated with cardiovascular disease. Led by a team of renowned experts in the field, including Michael Dixon, Peter McWilliams, Laurence Rulleau, and Andrew Jennings, Liphorus Pharmaceuticals combines groundbreaking scientific research with a forward-thinking management approach. With strategic partnerships with Univalor, IRCM, and Sanderling, Liphorus Pharmaceuticals is able to leverage their expertise, funding, and resources to accelerate the development of their groundbreaking treatments.

Stay updated with the latest news from Liphorus Pharmaceuticals, a brand committed to transforming healthcare and improving lives